← Back to Search

AI Screening Device

iROP DL for Retinopathy of Prematurity

N/A
Recruiting
Led By John P Campbell, MD/MPH
Research Sponsored by Siloam Vision
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to improve the image acquisition and processing pipeline for FDA approval. The researchers will evaluate how image quality and field of view affect the device's output and will assess the impact of different camera operators

Who is the study for?
This trial is for U.S. board-eligible or certified ophthalmologists who have signed consent forms, completed training on the study protocol and software, and agreed to participate in a reader study. It's focused on improving diagnosis of Retinopathy of Prematurity (ROP) using an AI system.
What is being tested?
The i-ROP DL system is being tested for its ability to accurately diagnose 'plus disease' in ROP through image analysis. The study will assess how image quality and camera operator influence results, aiming to validate the system as an autonomous AI screening device.
What are the potential side effects?
Since this trial involves non-invasive imaging with no direct patient interventions like drugs or surgery, there are no typical side effects associated with it. However, inaccuracies in diagnosis could potentially affect clinical decision-making.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitivity and Specificity of I-ROP DL for mtmROP
Secondary study objectives
Sensitivity and specificity of the I-ROP DL system for TR-ROP

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Reader StudyExperimental Treatment1 Intervention
Vascular Severity Score Provided on second reading

Find a Location

Who is running the clinical trial?

Siloam VisionLead Sponsor
1 Previous Clinical Trials
1,284 Total Patients Enrolled
1 Trials studying Retinopathy of Prematurity
1,284 Patients Enrolled for Retinopathy of Prematurity
National Eye Institute (NEI)NIH
558 Previous Clinical Trials
1,408,455 Total Patients Enrolled
16 Trials studying Retinopathy of Prematurity
5,926 Patients Enrolled for Retinopathy of Prematurity
John P Campbell, MD/MPHPrincipal InvestigatorOregon Health and Science University
1 Previous Clinical Trials
1,284 Total Patients Enrolled
1 Trials studying Retinopathy of Prematurity
1,284 Patients Enrolled for Retinopathy of Prematurity
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top